Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial

Bray, 2018, Global Cancer Statistics 2018: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA. Cancer J. Clin., 68, 394, 10.3322/caac.21492 He, 2019, Incidence and mortality of esophagus cancer in China, 2008-2012, Chin. J. Cancer Res., 31, 426, 10.21147/j.issn.1000-9604.2019.03.04 Qin, 2009, Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer, World J. Gastroenterol., 15, 871, 10.3748/wjg.15.871 Cao, 2009, A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer, Jpn. J. Clin. Oncol., 39, 582, 10.1093/jjco/hyp058 Wang, 2017, Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: a randomized, multicenter, open-label, controlled, phase 2b trial, Cancer, 123, 3986, 10.1002/cncr.30845 Moehler, 2020, Ann. Oncol., 31, 228, 10.1016/j.annonc.2019.10.018 Lorenzen, 2009, Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie, Ann. Oncol., 20, 1667, 10.1093/annonc/mdp069 Gibault, 2005, Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer, Br. J. Cancer, 93, 107, 10.1038/sj.bjc.6602625 Hanawa, 2006, EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus, Int. J. Cancer, 118, 1173, 10.1002/ijc.21454 Zhang, 2008, A phase II trial of paclitaxel and cisplatin in patients with advanced squamous-cell carcinoma of the esophagus, Am. J. Clin. Oncol., 31, 29, 10.1097/COC.0b013e3181131ca9 Cui, 2020, Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma, Cell Res., 30, 902, 10.1038/s41422-020-0333-6 Asan, 2017, Integrated genomic characterization of oesophageal carcinoma, Nature, 541, 169, 10.1038/nature20805 Lin, 2014, Genomic and molecular characterization of esophageal squamous cell carcinoma, Nat. Genet., 46, 467, 10.1038/ng.2935 Guigay, 2019, The evolving role of taxanes in combination with cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: evidence, advantages, and future directions, Front. Oncol., 9, 668, 10.3389/fonc.2019.00668 Hotz, 2012, In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype, Gastric Cancer, 15, 252, 10.1007/s10120-011-0102-9 Abal, 2003, Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action, Curr. Cancer Drug Targets, 3, 193, 10.2174/1568009033481967 Siddik, 2003, Cisplatin: mode of cytotoxic action and molecular basis of resistance, Oncogene, 22, 7265, 10.1038/sj.onc.1206933 Galluzzi, 2020, Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors, Nat. Rev. Clin. Oncol., 17, 725, 10.1038/s41571-020-0413-z Tsavaris, 2002, Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes, Br. J. Cancer, 87, 21, 10.1038/sj.bjc.6600347 Garnett, 2008, Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement, Clin. Cancer Res., 14, 3536, 10.1158/1078-0432.CCR-07-4025 Pfannenstiel, 2010, Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice, Cell Immunol., 263, 79, 10.1016/j.cellimm.2010.03.001 Shen, 2021, LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study, Ann. Oncol., 32, S1330, 10.1016/j.annonc.2021.08.2132 Wang, 2022, Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial, Cancer Cell, 40, 277, 10.1016/j.ccell.2022.02.007 Sun, 2021, Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study, Lancet, 398, 759, 10.1016/S0140-6736(21)01234-4 Doki, 2022, Nivolumab combination therapy in advanced esophageal squamous cell carcinoma, N. Engl. J. Med., 386, 449, 10.1056/NEJMoa2111380 Luo, 2021, Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial, JAMA, 326, 916, 10.1001/jama.2021.12836 Vermorken, 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer, N. Engl. J. Med., 359, 1116, 10.1056/NEJMoa0802656 Bossi, 2017, A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, Ann. Oncol., 28, 2820, 10.1093/annonc/mdx439 Tahara, 2018, Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02), Ann. Oncol., 29, 1004, 10.1093/annonc/mdy040 Tsakonas, 2020, Cancers (Basel), 12, 3110, 10.3390/cancers12113110 Sawada, 2016, Genomic landscape of esophageal squamous cell carcinoma in a Japanese population, Gastroenterology, 150, 1171, 10.1053/j.gastro.2016.01.035 Petty, 2017, Gefitinib and EGFR gene copy number aberrations in esophageal cancer, J. Clin. Oncol., 35, 2279, 10.1200/JCO.2016.70.3934 Janmaat, 2006, Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients, J. Clin. Oncol., 24, 1612, 10.1200/JCO.2005.03.4900 Ramos-Suzarte, 2012, Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy, Cancer Biol. Ther., 13, 600, 10.4161/cbt.19849 Chen, 2012, Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma, Cancer Sci., 103, 1979, 10.1111/j.1349-7006.2012.02393.x Zhu, 2018, A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification, J. Thorac. Dis., 10, 5328, 10.21037/jtd.2018.09.18 Herbst, 2018, Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study, Lancet Oncol., 19, 101, 10.1016/S1470-2045(17)30694-0 Bonomi, 2018, Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer, Ann. Oncol., 29, 1701, 10.1093/annonc/mdy196 Huang, 2020, Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study, Lancet Oncol., 21, 832, 10.1016/S1470-2045(20)30110-8 Kato, 2019, Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol., 20, 1506, 10.1016/S1470-2045(19)30626-6 Kojima, 2020, Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer, J. Clin. Oncol., 38, 4138, 10.1200/JCO.20.01888 Zhang, 2017, Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor, Cancer Sci., 108, 590, 10.1111/cas.13197 Sacco, 2021, Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial, Lancet Oncol., 22, 883, 10.1016/S1470-2045(21)00136-4 Feng, 2020, Integrative analysis of multi-omics data identified EGFR and PTGS2 as key nodes in a gene regulatory network related to immune phenotypes in head and neck cancer, Clin. Cancer Res., 26, 3616, 10.1158/1078-0432.CCR-19-3997 Maughan, 2011, Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomized phase 3 MRC COIN trial, Lancet, 377, 2103, 10.1016/S0140-6736(11)60613-2 Lu, 2016, Nimotuzumab plus paclitaxel and cisplatin as the first line treatment for advanced esophageal squamous cell cancer: a single centre prospective phase II trial, Cancer Sci., 107, 486, 10.1111/cas.12894 Ai, 2021, Clonal architecture of EGFR mutation predicts the efficacy of EGFR-tyrosine kinase inhibitors in advanced NSCLC: a prospective multicenter study (NCT03059641), Clin. Cancer Res., 27, 704, 10.1158/1078-0432.CCR-20-3063 Thorvaldsdóttir, 2013, Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration, Brief Bioinform., 14, 178, 10.1093/bib/bbs017